PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Yoon Jin, Kim, Dooreh, Bae, Soong June, Ahn, Sung Gwe, Jeong, Joon, Lee, Hye Sun, Jeon, Soyoung, Yoo, Tae-Kyung, Park, Woo-Chan, Yoon, Chang Ik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486819/
https://www.ncbi.nlm.nih.gov/pubmed/34599199
http://dx.doi.org/10.1038/s41598-021-97250-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486819/
https://www.ncbi.nlm.nih.gov/pubmed/34599199
http://dx.doi.org/10.1038/s41598-021-97250-2

Ejemplares similares